Program Book

Recommendations

Info

1547 Ump113 LONG-TERM OBSERVATIONS IN SMALL, POSTERIOR LOCATED MALIGNANT MELANOMAS OF THE CHOROID TREATED WITH TRANSPUPILLARY THERMOTHERAPY (TTT) B.M. Stoffelns, K. Schöpfer (bernhard.stoffelns@unimedizin-mainz.de) Department of Ophthalmology, Universal Medical Center of Johannes Gutenberg - University, Mainz, Germany, Purpose. To evaluate the long-term Results of transpupillary thermotherapy (TTT) for small malignant choroidal melanomas. Methods. In the time period 1.1998 to 10.1999 in a prospective nonrandomized analysis 26 eyes with small malignant melanomas (located posterior to the equator with base ≤ 12 and thickness ≤ 4,5 mm) were primary treated with the TTT standard protocol (follow-up over a time span of 10 years minimally). Results. Thirteen women and thirteen men (mean age 64 years) underwent TTT. The mean preoperative tumor thickness was 2,45 mm (0,8 – 4,5 mm). Ten years postoperatively tumor regression without recurrence after 1,4 treatment sessions (mean) was achieved in 16/26 eyes, primary regression followed by tumor regrowth in 6/26 eyes and primary failure of tumor regression in 4/26 eyes. Two patients died on liver metastasis. Ocular complications (with preference in posterior tumors after multiple TTT sessions) were observed in 14 eyes: macular pucker in 8, macular edema in 6, choroidal neovascularisation in 4 and posterior synechia with iris atrophy in one eye. Conclusions. Choroidal melanomas treated with TTT as stand-alone procedure need a close monitoring since these tumors developed a significant rate of local recurrences and ocular side-effects in the long run. Financial disclosure. None 602 Ump114 CANCER RISKS FOR PATIENTS WITH MYOTONIC DYSTROPHY Jose Pulido1, Aung Ko Win2, Promilla Perattur3, Christine Pulido3, Noralane Lindor3 pulido.jose@mayo.edu 1. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA; 2. Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Parkville, Victoria, Australia; 3. Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA. Purpose. Myotonic dystrophy (DM) types 1 and 2 are clinically similar autosomal dominant disorders and mainly characterized by myotonia, muscle weakness and early-onset cataracts. Several studies have suggested there may be increased risks for neoplasms associated with DM. We wished to quantify the risk Methods. A cohort of 307 DM patients identified from medical records from Mayo Clinic Rochester was retrospectively analyzed. We estimated standardized incidence ratios of specific cancers for DM patients compared with age- and sex-specific cancer incidences of the general population. Age-dependent cumulative risks were calculated using the Kaplan–Meier method. Results. A total of 54 cancers was observed at a median age at diagnosis of 55 years. DM patients were at an increased risk of thyroid cancer UVEAL MELANOMA Posters 112 (SIR 5.54, 95% CI 1.80-12.93, p=0.001), and choroidal melanoma (SIR 27.54, 95% CI 3.34-99.49, p3 Snellen visual acuity lines. OCT scans indicated improvement in retinal thickness over the lesion and in central retinal thickness in all treated cases. Two cases (one untreated and one treated with anti-VEGF) presented with outer retinal tubulation. There was no evidence of malignant transformation during follow-up. Conclusions. Anti-VEGF treatment was effective in achieving stable visual acuity (loss of
1617 Ump116 INCIDENCE OF METASTATIC DISEASE AND SURVIVAL OF 716 CONSECUTIVE PATIENTS WITH POSTERIOR UVEAL MELANOMA : A RETROSPECTIVE MONOCENTRIC REVIEW Fatima Hammouch1, Patrick De Potter2, David Francart3, François Dall’Armellina4, Jean-François Baurain5 (fatima.hammouch@uclouvain.be) 1. Oncology Department, Centre du Cancer, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain ; 2. Ophtalmology Department, Centre du Cancer, Cliniques Universitaires Saint-Luc; 3. Ophtalmology Department, Centre du Cancer, Cliniques Universitaires Saint-Luc ; 4. Oncology Department, Centre du Cancer, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain ; 5. Oncology Department, Centre du Cancer, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels. Purpose. To determine the rate, time and location of systemic metastases in patients with posterior uveal melanoma and to evaluate risk factors and survival after diagnosis of systemic relapse. Methods. A retrospective review was performed on 716 consecutive patients, referred and managed at the Centre du Cancer, Brussels, for posterior uveal melanoma, between January 1998 and December 2010. Data were analyzed with SPSS 18 for Mac. The rate of metastatic disease was calculated and patients survival was assessed by Kaplan- Meier method. The impact of metastatic diesase–related symptoms on survival was analyzed by the Log-Rank test. A multivariate Cox regression was performed to identify risk factors for metastatic disease. Results. The median age at diagnosis was 63 years. According to the COMS classification, there were 43 (6%) small tumors, 379 (53%) medium tumors, 232 (32%) large tumors and 62 (9%) tumors were unclassified. The treatment consisted in enucleation, radiotherapy +/- thermotherapy and thermotherapy alone in 24%, 66% and 10% of patients, respectively. The median time between tumor diagnosis and treatment was 9 days. The median time of follow up for the 716 patients was 3 years. Among them, 100 patients (14%) developed metastatic disease (71% exclusively liver localisation, 19% extraliver and liver localisations and 5% only extraliver localisation) with a median time to relapse of 32 months. The relapse free survival from diagnosis at 5 and 10 years was 81% and 75%, respectively. Risk factors for systemic metastases (multivariate analysis) were: large tumor (p=0.035), epitheloid cell melanoma (p=0.002) and later age at diagnosis (p=0.002). The median follow-up from relapse was 34 months. Fourty patients (40%) died from their melanoma with a median survival time of 17 months. No difference in survival was observed between those patients with metastasis-related symptoms and those without (p> 0.05). Conclusions. Even with a relatively short follow-up time (36 months), our study showed a lower rate (14%) of metastatic disease with a higher median survival time than those previously reported. Our cohort seemed to be homogeneous, with classical risk factors identified. While the issue of regular systemic screening on patient survival was not assessed, we did not find a significant difference between asymptomatic and systemic metastasis-related symptomatic patients. The potential impact of the treatment(s) on prognosis among our patients with metastatic disease is under investigation. Financial disclosure. None UVEAL MELANOMA Posters 113 25 Ump117 LONG LASTING SURVIVAL OF UVEAL MELANOMA WITH EXTRAOCULAR EXTENSION Ignacio Zeolite, Carlos Zeolite, Juan Oscar Croxatto (izeolite@yahoo. com) Oftar Mendoza, Universidad de Mendoza Purpose. To report a long term survival (over 60 months) of a patient with malignant melanoma with extraocular extension post diagnostic FNAB with no concomitant brachytherapy. Methods. A 80-year old female patient with malignant melanoma with extraocular extension post FNAB with no coadyuvant brachitherapy was treated with excisional biopsy of subconjunctival dark clumps diagnosed as extraocular extension of uveal melanoma. She refused any choice of treatment and was followed in a regular basis for 41 months. Results. Survival after FNAB with the diagnosis of malignant uveal melanoma was 51 months (46 months with extraocular extension). In this case we present an unusual pattern of extraoclar extension as multiple subconjunctival clumps with realatively long term stability while the general health status of the patient was well. At the time of the declining of the general health status the tumors grew fast and the patient died in 2 months with liver metastases. Enucleation was performed 50 months after FNAB because of ocular infection and tumor necrosis. No other choice of treatment was authorized for the patient nor the family. Conclusions. Malignant melanoma of the choroid can spread extraocularly after FNAB. Co-adyuvant brachitherapy is indicated after FNAB. Different patterns of extraocular extension can be observed. Long-term stability of the lesion can be associeted with good general health status. Financial disclosure. None 2133 Ump118 CLINICOPATHOLOGIC CORRELATIONS OF PLAQUE BRACHYTHERAPY FAILURE IN THE TREATMENT OF CHOROIDAL MELANOMA Jill R. Wells, Chris S. Bergstrom, Qing Zhang, Hans E. Grossniklaus (jrwells14@hotmail.com) Emory Eye Center, Oncology and Pathology Service Purpose. To correlate the histopathologic findings in the enucleated eyes of three patients who failed treatment for choroidal melanoma with plaque brachytherapy. Methods. Three patients who had undergone enucleation for failure of plaque brachytherapy for choroidal melanoma were identified. The clinical and histopathologic features of the enucleated eyes were reviewed as well as immunohistochemical staining. Results. Based on the clinicopathologic correlations, case 1 failed secondary to inadequate radiation to the peripheral tumor; case 2 failed secondary to inadequate radiation to the tumor over the nerve; and case 3 failed secondary to inherent radioresistance of the tumor. Conclusions. Careful attention to tumor ultrasound measurements and correct plaque design is important. Tumors overhanging the optic nerve are the difficult to treat. Further studies are needed to determine if and which cellular and genetic factors in choroidal melanomas underlie radioresistant cellular phenotypes. Financial disclosure. None
Page 1 and 2:
XV th NH City Hotel and Tower Boliv
Page 3 and 4:
List of Congress Meetings of the In
Page 5:
Table of Contents Welcome address K
Page 8 and 9:
Keynote Lectures Lymphoma of the oc
Page 10 and 11:
The venue for the Biannual Meeting
Page 12 and 13:
Buenos Aires Downtown MAP 12 Venue
Page 15 and 16:
MORNING 8.30-10.10 Papers (Moderato
Page 17 and 18:
50 RES 26 USING THE GLYCOLYTIC INHI
Page 19 and 20:
2226 RES 4 NOTCH SIGNALING PROMOTES
Page 21 and 22:
a reduction in the number of living
Page 23 and 24:
array further detected copy number
Page 25 and 26:
615 RES 21 TRB2 AND SKP2 IN THE RET
Page 27:
following treatment with 2-fluorode
Page 30 and 31:
1909 Rb14 RESULTS OF PATIENTS WITH
Page 32 and 33:
Posters Retinoblastoma 2006 RBp100
Page 34 and 35:
120 RBp135 MANAGEMENT OF AN ECTOPIC
Page 36 and 37:
After treatment, 10 patients lived
Page 38 and 39:
Methods. Six cycles of carboplatin
Page 40 and 41:
1940 RB15 PROTON THERAPY FOR RECURR
Page 42 and 43:
4. Fluoroscopy for cannula placemen
Page 44 and 45:
Methods. A retrospective chart revi
Page 46 and 47:
Ruth A. Kleinerman1, Chu-ling Yu1,
Page 48 and 49:
2006 RBp100 RETINOBLASTOMA ASSESSME
Page 50 and 51:
months. Mean delay between beginnin
Page 52 and 53:
not associated with severity of RB.
Page 54 and 55:
Conclusions. During a ten-year peri
Page 56 and 57:
30 RBp127 TREATMENT MODULATION IN R
Page 58 and 59:
(follow-up 5 years). Two years afte
Page 61 and 62: 8.30-9.00 Poster presentations ECOp
Page 63 and 64: Uvea (Moderators: B. Damato, M. Sag
Page 65 and 66: Morning 8.30-9.00 Poster presentati
Page 67 and 68: 1621 EC1 EVALUATION OF THE “HEDGE
Page 69 and 70: Purpose. Ocular surface squamous ne
Page 71 and 72: (cargusale@yahoo.com) Oncology Serv
Page 73 and 74: of the tissues most commonly affect
Page 75 and 76: 2128 RF1 RETINOBLASTOMA David H. Ab
Page 77 and 78: Ocular Oncology Service, St Barthol
Page 79 and 80: Arturo Irarrazaval, Pablo Cazon, Os
Page 81 and 82: A CASE OF TEARING AND SWELLING OF T
Page 83 and 84: 1849 ECp101 FIVE CASES OF CARCINOMA
Page 85 and 86: patients. The isolated involvement
Page 87 and 88: exudative fluid from the hemangioma
Page 89: maximum of 7 rituximab injections.
Page 92 and 93: 153 UM14 PHENO-GENOTYPIC IDENTIFICA
Page 94 and 95: 8.30-9.00 Poster presentations UMp1
Page 96 and 97: 2253 UM1 PRELIMINARY STUDY OF VASCU
Page 98 and 99: Purpose. To determine the presence
Page 100 and 101: gene expression profile of melanocy
Page 102 and 103: the rarity of UM, timely completion
Page 104 and 105: C. Metz, T. Gkika, W. Sauerwein, N.
Page 106 and 107: Patients in the triamcinolone group
Page 108 and 109: 1350 Ump101 INDUCED EXPRESSION OF P
Page 110 and 111: Purpose. To report the Results of R
Page 114 and 115: 2038 Ump119 VALUE OF DOPPLER ANALYS
Page 116: Methods. A total of 4070 patients w
Page 119: First authors Naseripour, Masood No
show all

Program Book

Create successful ePaper yourself

Delete template?

Save as template?